| Literature DB >> 18454307 |
Maria Sundvall1, Kristiina Iljin, Sami Kilpinen, Henri Sara, Olli-Pekka Kallioniemi, Klaus Elenius.
Abstract
Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18454307 DOI: 10.1007/s10911-008-9079-3
Source DB: PubMed Journal: J Mammary Gland Biol Neoplasia ISSN: 1083-3021 Impact factor: 2.673